---
title: Cost-effectiveness analysis of plasmapheresis and hemoperfusion in COVID-19 survivors after hospital discharge
date: 2024-05-20
tags:
  - R
  - SPSS
  - COVID-19
---

Status: Manuscript submitted, in review

<!--more-->
ICU-discharged patients were followed up to six-months. Vital signs, laboratory markers, quality of life and direct medical costs data were bootstrapped to calculate incremental cost-effectiveness ratios (ICER) and plot cost-effectiveness planes and acceptability curves.



Quality of Life Assessment: quality-adjusted life years (QALY) via EQ-5D-5L questionnaire and WHO life table

Expenses: bottom-up macro-costing approach from the provider's perspective

Related-Samples Wilcoxon Signed Rank Test

R (non-parametric bootstrapping, Incremental cost-effectiveness ratio (ICER), cost-effectiveness scatterplots and cost-effectiveness acceptability curves